| P50 | author | Kevin J Horgan | Q56797386 |
| P2093 | author name string | Sant P Chawla | |
| | Paul J Hesketh | |
| | Richard J Gralla | |
| | Alexandra D Carides | |
| | Judith K Evans | |
| | Mary E Elmer | |
| | Steven M Grunberg | |
| | Arlene Taylor | |
| | Carrie Schmidt | |
| | Cindy Rittenberg | |
| P2860 | cites work | Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology | Q33880234 |
| | Potential of substance P antagonists as antiemetics | Q33921293 |
| | Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis | Q34057610 |
| | Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients | Q34746953 |
| | The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor | Q35872537 |
| | Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists | Q36431212 |
| | On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. | Q39428685 |
| | Neurotransmitter functions of mammalian tachykinins | Q40486282 |
| | Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists | Q40655344 |
| | Control of chemotherapy-induced emesis | Q40776391 |
| | Proposal for classifying the acute emetogenicity of cancer chemotherapy | Q41314646 |
| | Consequences of high-dose steroid therapy for acute spinal cord injury | Q41356096 |
| | Drug treatment of chemotherapy-induced delayed emesis | Q41445456 |
| | Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity | Q43453834 |
| | Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone | Q43543624 |
| | Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis | Q43582725 |
| | Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. | Q44062377 |
| | Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group | Q48300913 |
| | Septic complications of corticosteroid administration after central nervous system trauma | Q48465375 |
| | A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. | Q53364609 |
| | Risk of infectious complications in patients taking glucocorticosteroids | Q69561570 |
| | Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets | Q71605902 |
| | The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret | Q72270820 |
| | The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets | Q73574723 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 2290-2300 | |
| P577 | publication date | 2003-05-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting | |
| P478 | volume | 97 | |